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Abstract
Background. Prognosis of fetuses with renal oligohy-
dramnios (ROH) is often still regarded as poor.
Neonatal complications and the long-term follow-up
of fetuses with ROH in two pediatric centres are
described.
Method. 23 fetuses (16 males, 7 females) were included
as patients. Primary diseases included congenital
anomalies of the kidney and urinary tract (n¼ 16),
autosomal recessive polycystic kidney disease (n¼ 4)
and renal tubular dysgenesis (n¼ 3). The analysis
includes retrospective chart review.
Results. Seven children died (30%), the majority
(n¼ 4, 17%) within the neonatal period due to
pulmonary hypoplasia and renal insufficiency.
Fourteen patients (61%) required postnatal mechan-
ical ventilation for a median of 4 (range 1–60) days;
11 infants had an associated pneumothorax. All 16
surviving children have chronic kidney disease (CKD)
at a current median age of 5.7 years (range 0.5–14.5),
managed conservatively in eight patients [median glome-
rular filtration rate 51 (range 20–78) ml/min/1.73m2].
Eight patients reached end-stage renal disease at a
median age of 0.3 years (range 2 days to 8.3 years),
including one patient with pre-emptive kidney
transplantation. Five of the patients requiring dialysis
underwent successful renal transplantation at a median
age of 3.5 years (range 2.5–4). Growth was impaired in
seven children requiring growth hormone treatment.
Cognitive and motor development was normal in 12
(75%) of the 16 patients and showed a delay in four
children, including two with associated syndromal
features.
Conclusion. ROH is not always associated with a poor
prognosis and long-term outcome in survivors is
encouraging. The high incidence of neonatal complica-
tions and long-term morbidity due to CKD requires a
multidisciplinary management of these children.
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Introduction
Congenital anomalies of the kidney and urinary tract
(CAKUT) are detected frequently in up to 1% of
newborns, and nowadays diagnosis is often established
before birth by fetal ultrasound. If CAKUT occurs
unilaterally, e.g. hydronephrosis due to ureteropelvic
or ureterovesical junction obstruction, or multicystic
renal dysplasia, prognosis is generally good [1,2].
Bilateral renal disease with oligohydramnios, how-
ever, indicates significant global fetal renal dysfunction
and is a risk factor for the development of pulmonary
hypoplasia [3,4]. Outcome for fetuses with renal
oligohydramnios (ROH) therefore is regarded as
poor. In a series from the Mayo Clinic, 18 of 52
(32%) children with CAKUT had oligohydramnios
and all children died, including six intrauterine deaths
[5]. As fetal and neonatal survival is at risk, termina-
tion of pregnancy is frequently practised in this
situation [6].
This is in striking contrast to the dramatic progress
that has been made in neonatal intensive care including
pulmonary management. Also, recent advances in
treatment of infants and children with chronic kidney
disease (CKD) and end-stage renal disease (ESRD)
has improved prognosis also for infants with renal
insufficiency considerably [7–10]. Precise information,
however, on the clinical situation on short- and long-
term outcome data for fetuses presenting with ROH
is scarce. In some series of patients with urological
disorders, children with ROH are probably included;
however, specific details are missing. For instance,
in the series by Drozdz et al. [11] three of 20 boys
with posterior urethral valves required mechanical
ventilation; however, no details on the presence of
oligohydramnios are given.
The aim of our study was to obtain comprehensive
data on short- and long-term outcome of 23 fetuses
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with ROH that have been followed in our centres since
1990. This included a detailed analysis of (i) neonatal
pulmonary and renal course, (ii) long-term renal
outcome as well as (iii) extrarenal morbidity (growth
and development).
Patients and methods
A total of 23 infants (16 males, 7 females) with an antenatal
diagnosis of ROH that were followed in our centres after
birth were included. Data were analysed retrospectively
by chart review. Fourteen infants were delivered in our
institutions and nine were referred from regional hospitals,
all for further treatment of renal disease. Patients were
diagnosed between 1990 and 2005. Twelve were followed
at the University of Hamburg Children’s Hospital (center 1)
and 11 at the Children’s Hospital of the University of Zurich
(center 2). Median gestational age was 37 weeks (range 34–40
weeks). Patient details are presented in Table 1.
Oligohydramnios was defined as the generalized decrease
in amniotic fluid. The vertical horizontal diameter of the
largest pocket was less than 2 1 cm2 in ultrasound
investigation [12,13]. The oligohydramnios was detected at
a median of 30 weeks gestation (range 14–37) in 21 cases:
four in the second and 17 in the third trimenon. In two
pregnancies, diagnosis of ROH was established immediately
prior to birth due to poor maternal compliance with routine
antenatal obstetrical visits.
Most children (n¼ 16) had CAKUT: eight infants had
posterior urethral valves with associated renal dysplasia,
five had bilateral renal dysplasia including one patient with
VACTERL association, one patient had bilateral multicystic
dysplastic kidneys and two patients had prune-belly
syndrome with associated renal anomalies. In addition,
four patients had autosomal recessive polycystic kidney
disease (ARPKD) and three siblings had renal tubular
dysgenesis.
For comparison of parametrical variables the Mann–
Whitney U-test was used and for survival analysis the log-
rank test (Mantel Cox) were computed using SPSS 13.0. A
P< 0.05 was considered to be statistically significant.
Results
Mortality
Of the 23 patients seven died (30%; Figure 1 and
Table 1). Four patients (17%) died in the neonatal
period due to pulmonary hypoplasia and terminal
renal insufficiency. None of these infants was dialysed.
Three patients died later: one patient with additional
multiple cardiac anomalies due to cardiomyopathy at
3.5 months, one patient with associated VACTERL
anomalies due to pulmonary hypertension and renal
insufficiency at the age of 5 months and one patient
with ARPKD due to sepsis at the age of 14.5 months.
Non-survivors had a significantly earlier diagnosis
of ROH than survivors (median 25 weeks, range
14–35 vs 31, 19–37; P< 0.05. Of four fetuses with ROH
diagnosed in the second trimenon, two died compared
with 5/17 fetuses diagnosed in the third trimenon.
Using the diagnostic median of 30 weeks as cutoff,
diagnosis of ROH prior to this was associated with a
higher overall mortality (6 of 10) than diagnosis
after 30 weeks gestation (1 of 11; P< 0.02; Figure 2).
Also, neonatal mortality was more frequent in fetuses
with a diagnosis prior to 30 weeks (4/10 vs 0/11,
P< 0.03).
Neonatal course
Pulmonary outcome. Fourteen neonates (61%),
including six of the seven non-survivors required
artificial ventilation for a median of 4 (range 1–60)
days, including one child with nasal continuous
positive airway pressure (CPAP). Four neonates with
antenatally suspected pulmonary hypoplasia did not
need ventilation. Pneumothorax occurred in 11 infants,
including one patient that did not require respiratory
support.
Renal outcome. Neonatal renal dysfunction occurred
in 20 of 23 children (87%). Most frequently, electrolyte
imbalances and metabolic acidosis (n¼ 14) were
present. Hypertension was diagnosed in the neonatal
period in two infants with ARPKD. Severe
renal dysfunction occurred in eight patients, including
three of the non-survivors, who were not dialysed
(patients 2–4).
Four patients (all survivors) required peritoneal
dialysis in the neonatal period; however, only two for
the first postnatal weeks. The other two patients
started dialysis at day 3 and 4, respectively, and
continued renal replacement therapy without major
problems until renal transplantation (RT). One
surviving patient with severe renal dysfunction suffered
from superimposed pre-renal failure, that could be
managed conservatively.
Long-term course
Long-term renal outcome and morbidity
(Figure 3). The surviving 16 children have a current
median age of 5.7 (range 0.5–14.5) years. All developed
CKD, which was managed conservatively in
eight patients (50%), with a median glomerular
filtration rate (GFR) of 51ml/min/1.73m2 (range
20–78).
Eight of 16 patients (50%) required renal replace-
ment therapy at a median age of 0.3 years (range 2 days
to 8.3 years); seven were started on peritoneal dialysis;
however, two later switched to haemodialysis. One
patient underwent pre-emptive kidney transplantation
(KT) at age 8 years. Five of the children requiring
dialysis received a successful renal graft at a median
age of 3.5 years (range 2.7–4). Early diagnosis of ROH
did not predict the risk of ESRD.
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Table 1. Individual patient data
Patient Sex Renal and extrarenal
diagnosis
First
diagnosis of
ROH (GW)
Gestation
(weeks)
Mechanical
ventilation
(days)
Pneumo-
thorax
Neonatal pulmonary
and renal problems
and outcome
Renal follow-up Development and growth;
duration of follow-up
1 m PUV 18 39 No No Respiratory failure,
died in delivery room
2 m PUV, bilateral renal
dysplasia
28 38 Yes (28) Yes ESRD (no dialysis).
Died after 4 weeks (HMD)
3 f Tubular dysgenesis,
sister of 16
25 35 Yes (4) Yes ESRD (no dialysis) and
respiratory failure,
died after 4 days (HMD)
4 f Tubular dysgenesis,
sister of 16
26 34 Yes (2) Yes ESRD (no dialysis) and
respiratory failure,
died after 2 days
5 f ARPKD 29 35 Yes (7) Yes Ventilation, no renal
problems
Hypertension,
cardiomyopathy, CKD,
died after 14.5 months
(pseudomonas sepsis)
6 m ARPKD, Multiple
cardiac anomalies
35 39 No No CKD Died after 3.5 months
due to CKD and
cardiomyopathy
7 m Vacterl-association
with bilateral
renal dysplasia
14 34 No No Colostomy, pulmonary
hypertension
Died after 5 months of
CKD and pulmonary
hypertension
8 m Bilateral renal dysplasia 33 (amniotic
infusion)
40 No No CKD, Acidosis ESRD, PD started
age 8.3, switched
to HD age 8.7
GH since age 3.9, Height
SDS 1.59, 11.8 years
9 m ARPKD 32 37 Nasal CPAP (1) No CKD, Hypertension GFR 20ml/min/1.73m2 Height SDS 0.59,
7.5 years
10 f Bilateral renal dysplasia 28 38 Yes (22) No ESRD, PD since day 4 PD started day 4 to
age 2.9 until KT
GH age 1.5–2.9, Height
SDS 2.4, 6.1 years
11 m PUV, bilateral renal
dysplasia
20 37 Yes (5) Yes acute pre-renal failure,
feeding problems
PD age 1.2, KT age 3.5 Developmental delay,
GH age 1.0 to KT,
Height SDS 2.65,
6.1 years
12 f Bilateral renal dysplasia,
Syndromal features
36 40 No No CKD CKD, GFR
52ml/min/1.73m2
Development delay,
Height SDS 2.6,
5 years
4
3
4
I.
K
la
a
ssen
et
a
l.
13 m PUV, prune-belly
syndrome
19 (amniotic
infusion)
35 Yes (5) No CKD ESRD, PD age 0.2,
switched to HD age 2.3,
KT age 4.0
GH age 1.0 to KT,
Height SDS 1.2,
5.2 years
14 m PUV, Trisomy 21
syndrome
unknown 36 No No CKD, recurrent
pyelonephritis
CKD, GFR
78ml/min/1,73m2
Developmental delay,
Height SDS 2.7,
3.3 years
15 m Prune-belly syndrome
with renal dysplasia,
megacystis
34 35 No Yes CKD PD age 0.5, KT age 3.5 GH age 1.5 to KT,
Height SDS 2.9,
4.6 years
16 m PUV, bilateral renal
dysplasia
33 37 Yes (7) Yes CKD PD started age 0.25 Height SDS 0.5,
1.7 years
17 f Multicystic renal
dysplasia
unknown 40 Yes (4) No ESRD PD started day 3 PD until KT at
age 2.5 years
GH age 1.0 to KT,
Height SDS 2.5,
3.4 years
18 m PUV, VUR 32 34 Yes (60) Yes Acute renal failure, PD for
21 day, small-bowel-perforation,
myocardial infarction, sepsis
GFR 45ml/min/1.73m2 Mild developmental delay,
Height SDS 1.58,
6 months
19 m PUV, bilateral renal
dysplasia
37 38 Yes (3) Yes CKD GFR 69ml/min/1.73m2,
Enuresis
Height SDS 0.1, 7.7 years
20 m Bilateral renal dysplasia,
vesico-ureteral reflux
36 40 No No CKD CKD, GFR
50ml/min/1.73m2
Height SDS 1.9, 7.9 years
21 m ARPKD 30 36 Yes (1) Yes CKD, Hypertension CKD until preemptive
KT at age 8.0
GH age 4.0–7.5 Height
SDS 0.0, 14.5 years
22 f Tubular dysgenesis 28 38 Yes (26) Yes Acute renal failure,
PD for 4 weeks
CKD, GFR
47ml/min/1.73m2,
hyperparathyroidism
Height SDS 1.59,
14.3 years
23 m PUV, bilateral renal
dysplasia
32 34 No No CKD, maximum. serum
creatinine 3.1mg/dl
GFR 60ml/min/1,73m2 Height SDS 0.18, normal
development, 9 months
ARPKD, autosomal recessive polycystic kidney disease; CKD, chronic kidney disease; ESRD, end-stage renal disease; GH, growth hormone; HMD, hyaline membrane disease; KT, kidney
transplantation; ROH, oligohydramnios of renal origin; PD, peritoneal dialysis; PUV, posterior urethral valves; VUR, vesico ureteric reflux; GFR, glomerular filtration rate.
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Extrarenal morbidity
Growth. Current median height of the 16 children
is 1.59 standard deviation (SDS) (range 2.9 to
þ0.9); (Figure 4). Seven patients required treatment
with recombinant growth hormone (GH) for a median
period of 3.5 years (range 1.5–7.2), which was
discontinued at the time of renal transplantation.
One patient on haemodialysis still receives GH. Two
patients with SDS <2 currently show catch-up
growth after RT.
Development. Gross cognitive and motor development
is normal in 12 of 16 patients (75%). They have
normal motor function and attend normal schools
(primary school: n¼ 3, secondary school: n¼ 3,
kindergarten; n¼ 4, excluding two patients younger
than 3 years).
Developmental delay is present in four children. One
patient with concomitant birth asphyxia (patient 11)
developed spastic quadriplegia (legs more than arms)
with minor cognitive deficits, but attended kindergarten.
One girl (patient 12) with associated congenital
muscular hypotonia, clubfeet and dysmorphic facial
features has moderately delayed motor and speech
development but attends kindergarten. One patient
(patient 14) has Down’s syndrome, with associated
developmental delay and muscular hypotonia.
One patient after a protracted neonatal course and
long-term ventilation and multiple complications
(patient 18) has muscular hypotonia and feeding
problems.
Survival (months)
1.0
0.8
0.6
0.4
0.2
0.0
Cu
m
ul
at
iv
e 
su
rv
iv
al
Diagnosis >30
weeks
Diagnosis <30
weeks
P < 0.03 
Fig. 2. Cumulative survival is significantly worse (P< 0.03) in infants with a diagnosis of ROH before the 30th gestational week.
Fig. 1. Schematic representation of survival in patients with ROH.
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Discussion
This report indicates that not all fetuses with ROH
have a poor outcome. Although neonatal mortality
and morbidity are significant, multidisciplinary efforts
can result in an encouraging long-term prognosis.
Although all surviving patients have CKD, sometimes
requiring renal replacement therapy from the first days
of life, the majority of patients can be managed
conservatively.
Very few data on early neonatal outcome of ROH
are available. One reason for this might be the fact that
termination of pregnancy is still frequently practised
for fetuses with ROH [6]. In contrast, one recent study
documented a survival of 91% for male patients
with ROH, lower urinary tract obstruction and
vesicoamniotic shunting [14]. No precise data,
however, on neonatal and long-term morbidity
were stated in this publication. In a study from
Zaccara et al. [15], 12 of 18 patients with an
intrauterine diagnosis of bladder outlet obstruction
and ROH could be followed-up after birth; of these,
three died due to pulmonary hypoplasia compared
with none in a group without ROH.
Our study for the first time presents detailed data on
the neonatal clinical course after ROH, extending a
previous limited experience in 10 patients [16].
Pulmonary complications due to pulmonary
Fig. 3. Schematic representation of individual clinical course in survivors (dark grey: conservative treatment, light grey: peritoneal dialysis,
chequered pattern: haemodialysis, and black: kidney transplantation).
Fig. 4. Present height SDS of the survivors (filled circle with GH-treatment, filled square without GH-treatment).
Antenatal oligohydramnios of renal origin 437
hypoplasia and pneumothorax were frequent, and
most children required assisted ventilation. Initial
management in a neonatal intensive care setting is
therefore mandatory, and affected fetuses should
ideally be referred to tertiary perinatal centers. This
need is further underlined by the fact that respiratory
failure may also increase the risk of perinatal asphyxia
impairing long-term neurological outcome. Antenatal
sonographic suspicion of pulmonary hypoplasia,
however, was not a specific prognostic marker, as
some of these neonates had an uncomplicated
pulmonary course without need for oxygenation or
ventilation. Even sophisticated technology such as
magnetic resonance-calculation of lung volumes in
fetuses with ROH failed to predict the postnatal
pulmonary course [17].
Whether antepartum amnioinfusion is a way to
prevent or ameliorate pulmonary hypoplasia in
neonates is a matter of debate. Experimental evidence
is in favour and supported by recent studies; however,
prospective data for ROH are lacking [9,18–20].
Two patients in our series received amnioinfusion
treatment, but the series is too small to allow
conclusions. Also, the value of antenatal surgery in
ROH due to obstructive uropathies to improve
pulmonary (and renal) function is under debate and
is currently viewed with caution [21].
In the neonatal period, only a minority of patients in
our series actually needed dialysis, comparing data of
infants with other causes of neonatal renal failure [22].
Neonatal renal dysfunction, electrolyte disorders or
hypertension, however, were present in almost all
patients. Thus, nephrological expertise is necessary for
optimal treatment. In addition, some patients required
urological interventions, again underlying the multi-
disciplinary approach, including diagnostic imaging
facilities and genetic expertise. The latter is demon-
strated by the heterogeneous postnatal course in a
family with three fetuses suffering from renal tubular
dysgenesis [23]. Whether more aggressive treatment of
renal insufficiency (e.g. dialysis in all patients with
severe renal dysfunction), further improves
outcome, cannot be concluded from our data.
The long-term outcome is mainly influenced by the
degree of CKD. Although care of infants with CKD
is a challenge, recent reports demonstrate a good
prognosis so that treatment is recommended [24]; this
notion is also supported by our results. A large
proportion of these patients can be managed con-
servatively for a long time, despite antenatal evidence
of severe renal disease [7]. Unfortunately, efforts to
objectively assess fetal renal function non-invasively
and accurately remains unsatisfactory [25].
Extrarenal morbidity includes growth retardation,
which can be managed successfully by optimized
nutrition, growth hormone and erythropoietin treat-
ment and RT. Neurological outcome, though not
evaluated prospectively and in precise detail, is
appropriate for age in most patients. Two children
with developmental delay had associated congenital
anomalies. Future efforts should also focus on
elimination of additional risk factors for develop-
mental delay, such as perinatal asphyxia present in one
of our patients. However, our data clearly indicate
that renal dysfunction in a patient without asphyxia
is not a risk factor for adverse neurological outcome,
although neonates with asphyxia often have renal
dysfunction [3].
Of the potential risk factors discussed, early
diagnosis of ROH, i.e. occurrence in the first and
second trimester, has been regarded an indicator of
poor outcome [26] but not unanimously [13]. In some
series, patients with cardiac malformations and termi-
nation of pregnancies were included. In our series,
patients with poor overall survival had a significantly
earlier diagnosis; however, this has to be viewed with
caution, since early diagnosis is not able to differentiate
between poor and good outcome. Individual patients
with a very early diagnosis did well and vice versa some
patients with late (or delayed) diagnosis died or had
poor renal outcome. Mortality after the neonatal
period, e.g. due to sepsis and heart disease is not
always and necessarily related to ROH. Furthermore,
interindividual fetal diagnostic accuracy as well as
patient compliance with antenatal routine visits will
remain a problem and results may not always be
reliable. Nevertheless, early presentation of ROH must
be viewed critically and future studies should prospec-
tively address the predictive value of antenatal
sonographical tools, e.g. time of diagnosis and other
indices of severity.
The present observation is limited by the selected
patient group, limited sample size and the retrospective
analysis. Only fetuses followed in our tertiary pediatric
nephrology centres were included, thus excluding
fetuses not surviving intrauterine life due to intrauter-
ine death or termination of pregnancy. Nevertheless,
we believe that our conclusions are valid, since all
infants with postnatal care were included, indicating
that an overall negative prognosis for fetuses with
ROH is not justified. This has important consequences
for antenatal and genetic counseling. Our data confirm
the obligation to implement a clinic for antenatal
counseling for fetuses with CAKUT and renal
disorders. Especially if ROH is present, the multi-
disciplinary approach has to be established before
birth, including a neonatologist and pediatric nephrol-
ogists. Counseling of affected families should aim at
neutral, balanced information to parents with indivi-
dualized, independent decisions according to the
family situation.
In summary and conclusion, our data indicate that
the majority of fetuses with ROH have an encouraging
long-term prognosis if a multidisciplinary approach is
available [27]. Future efforts should include improved
antenatal detection of risk factors and interdisciplinary
antenatal counseling. If a decision is made to deliver
the fetus, referral to a tertiary neonatal and pediatric
nephrology centre seems mandatory.
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